Abstract
The incidence of head and neck squamous cell carcinoma (HNSCC) is on the rise and is expected to increase by 50% by 2030. Around half of the patient population affected are diagnosed when the tumor is at a locally advanced stage. These patients are usually treated with intense radiotherapy, leading to severe side-effects. Precision medicine would revolutionize the treatment of head and neck cancer by accurately identifying patients that are at low risk of recurrence, reduce treatment related side-effects and aid in overall improvement in quality of life of patients after treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
